Ionis Pharmaceuticals Stock Price, News & Analysis

On August 24, 2020, Akcea Therapeutics and Ionis Pharmaceuticals announced that data from the Phase 2 clinical trial of vupanorsen (AKCEA-ANGPTL3-L_Rx) will be presented at the ESC Congress 2020, scheduled for August 29-September 1, 2020. Vupanorsen is an investigational therapy targeting cardiovascular diseases by reducing ANGPTL3 protein levels in patients with conditions such as hypertriglyceridemia and type 2 diabetes. The companies previously secured a $250 million licensing deal with Pfizer, which will assume further development responsibilities.

Akcea Therapeutics and Ionis Pharmaceuticals announced that data from the Phase 2 study of AKCEA-APOCIII-L_Rx will be presented at the ESC Congress 2020 from August 29 to September 1, 2020. The drug aims to reduce apolipoprotein C-III levels, a protein linked to triglyceride regulation and cardiovascular risk. Previous studies showed promising results, with dose-dependent reductions in triglycerides and increases in HDL-C. This presentation may influence the drug's market potential and investor outlook.

Akcea Therapeutics has announced new pricing and reimbursement terms for WAYLIVRA^® (volanesorsen) in Germany, effective August 15, 2020. This renegotiation, required 12 months post-commercialization, highlights the drug's value for patients with familial chylomicronemia syndrome (FCS) at high risk for pancreatitis. WAYLIVRA is now the only therapy approved for FCS in the EU, following its launch in August 2019. Akcea aims to expand WAYLIVRA's availability to more European countries, supporting the needs of patients suffering from this ultra-rare disease.

Ionis Pharmaceuticals reported Q2 2020 results, achieving a non-GAAP net income of $8 million despite a GAAP net loss of $32 million. Revenue rose to $146 million, driven by $72 million in SPINRAZA royalties and increased product sales. Ionis maintains its 2020 financial guidance, targeting profitability. The company has over $2.3 billion in cash, supporting future initiatives. Progress includes advancements in neurological and cardio-renal programs, with expectations for multiple marketing applications through 2025. Key studies for new treatments are set to begin, enhancing growth potential.

Ionis Pharmaceuticals (NASDAQ: IONS) will host a live webcast on August 5, 2020 at 11:30 a.m. ET to discuss its Q2 2020 financial results and provide updates on its pipeline and business progress. This event will focus on the company's advancements in RNA-targeted drug discovery, highlighting their innovative antisense technology that addresses unmet medical needs.

Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, will host a live webcast on August 4, 2020, at 4:30 p.m. ET to discuss its Q2 2020 financial results and pipeline progress. The company's medicines, including TEGSEDI and WAYLIVRA, target serious and rare diseases. With a robust pipeline, Akcea is poised for future growth in the biopharmaceutical sector.

Investors can access the webcast at this link.

Akcea Therapeutics (NASDAQ: AKCA) announces the appointment of Christophe Hotermans, M.D., Ph.D., as senior vice president of global medical affairs. With over 20 years of experience, including a decade at Biogen, Dr. Hotermans will lead the company's medical strategies and operations worldwide. His expertise in specialty care and rare diseases aligns with Akcea's goals, focusing on the commercial launch of TEGSEDI and WAYLIVRA. Akcea, a majority-owned affiliate of Ionis Pharmaceuticals (NASDAQ: IONS), continues to develop medicines for serious and rare diseases, supported by a strong pipeline.

Ionis Pharmaceuticals (NASDAQ: IONS) will host a live webcast on July 14, 2020, at 10:00 a.m. Eastern Time to discuss its neurology franchise. The presentation will feature key executives, including CEO Brett P. Monia and Chief Scientific Officer Frank Bennett, covering various neurological diseases like Amyotrophic Lateral Sclerosis, Alzheimer's, Parkinson's, and more. Participants can access the webcast through Ionis' website, where a replay will also be available.

Ionis is recognized for its leadership in RNA-targeted therapeutics.

Akcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals (NASDAQ:IONS), will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 3:30 p.m. ET. CEO Damien McDevitt and CCO Kyle Jenne will represent the company in this virtual event. Participants can access the live webcast through Akcea's website.
Akcea focuses on developing drugs for serious and rare diseases, including TEGSEDI and WAYLIVRA, leveraging Ionis' proprietary technology.